REX AI Equity Premium Income ETF vs Philip Morris International Inc. — how do they compare? REX AI Equity Premium Income ETF trades at $37.3, while Philip Morris International Inc. trades at $185.58 (market cap $290.24B). The key difference: Philip Morris International Inc. pays a 3.16% dividend while REX AI Equity Premium Income ETF pays none, and Philip Morris International Inc. is trading nearer its 52-week high, REX AI Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| AIPI | PM | |
|---|---|---|
Sector | Income / Options Overlay | Consumer Staples |
52-Week High | $44.93 | $200.17 |
52-Week Low | $32.45 | $144.33 |
Market Cap | — | $290.24B |
Enterprise Value | — | $333.36B |
Dividend Yield | — | 3.16% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Philip Morris International (PM) trades at $186.22, down 1.77% with mixed technical signals. The company reported strong Q1 and Q2 2026 earnings beats but faces margin pressure from rising costs. Revenue grew to $40.65B in 2025 with a robust 25.56% net income margin. Analyst consensus remains bullish with a $211.17 price target, though recent news highlights challenges including a $500M impairment charge and increased illicit cigarette trade in Europe.
PM offers solid fundamentals with high profitability and dividend yield, but near-term headwinds from cost inflation and regulatory risks warrant caution. The stock's valuation at 25.54x P/E is reasonable given earnings growth potential, making it attractive for long-term investors despite current volatility.
Trailing returns across standard periods
Latest headlines on both assets
AIPI provides exposure to leading artificial intelligence firms while seeking to generate monthly income. It uses a covered call strategy to capture premiums from the volatility of AI-related stocks.
Read more on AIPI →Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →